| Literature DB >> 27045926 |
Valeria D'Argenio1,2, Giorgio Casaburi1, Vincenza Precone1,2, Chiara Pagliuca1,2, Roberta Colicchio2, Daniela Sarnataro1,2, Valentina Discepolo1,3, Sangman M Kim4, Ilaria Russo5, Giovanna Del Vecchio Blanco6, David S Horner7, Matteo Chiara7, Graziano Pesole8,9, Paola Salvatore1,2, Giovanni Monteleone6, Carolina Ciacci5, Gregory J Caporaso10, Bana Jabrì4, Francesco Salvatore1,2,11, Lucia Sacchetti1.
Abstract
OBJECTIVES: Celiac disease (CD)-associated duodenal dysbiosis has not yet been clearly defined, and the mechanisms by which CD-associated dysbiosis could concur to CD development or exacerbation are unknown. In this study, we analyzed the duodenal microbiome of CD patients.Entities:
Mesh:
Year: 2016 PMID: 27045926 PMCID: PMC4897008 DOI: 10.1038/ajg.2016.95
Source DB: PubMed Journal: Am J Gastroenterol ISSN: 0002-9270 Impact factor: 10.864
Clinical and laboratory features of the three groups enrolled in the study
| No. of subjects | 15 | 20 | 6 |
| Age in years (Mean±s.d.) | 42±16 | 38±12 | 39±11 |
| Sex F/M (%F) | 13F/2M (85%) | 18F/2M (89%) | 5F/1M (83%) |
| Anemia | 6/15 (40%) | 9/20 (45%) | 1/6 (17%) |
| Weight loss | 1/15 (7%) | 2/20 (10%) | 0/6 (0%) |
| Diarrhea | 1/15 (7%) | 5/20 (25%) | 2/6 (33%) |
| Dyspepsia and/or IBS | 7/15 (47%) | 10/20 (50%) | 2/6 (33%) |
| Chronic gastritis | 2/15 (13%) | 0/20 (0%) | 0/6 (0%) |
| GERD | 5/15 (33%) | 0/20 (0%) | 0/6 (0%) |
| Presence of CD antibodies (EMA and/or TG2 IgA) | 10(+), 5 | 20 (+)/20 | 0 (+)/6 |
| Positive family history of CD (%) | 1/15 (7%) | 5/20 (25%) | 1/6 (17%) |
| Duodenal biopsy (Marsh Index) (%) | 15/15 M0 (100%) | 4/20 M3A (20%) 8/20 M3B (40%) 8/20 M3C (40%) | 4/6 M0 (67%)
2 |
CD, celiac disease; EMA, antiendomysium IgA; F, female; GERD, gastroesophageal reflux disease; GFD, gluten-free diet; IBS, irritable bowel syndrome; M, male; TG2, anti tissue-transglutaminase 2 IgA.
Iron-deficiency anemia.
Not assayed in GERD.
Partial villous atrophy and intra-epithelial lymphocyte count =25/100.
Figure 1Duodenal microbiome taxonomic composition in controls, in active and in gluten-free diet (GFD) celiac disease (CD) patients. (a) Relative abundance at phylum level. Proteobacteria was the most abundant phylum in all 3 groups with an average abundance of 39.3%. (b) Class level classification in the 3 groups showed a decreasing trend for the Betaproteobacteria class in GFD patients (4%) and controls (10%) versus CD patients (26%). The Gammaproteobacteria class was less abundant in CD patients (21%) than in controls (28%) and GFD patients (30%). (c) Order level classification revealed a significant difference (P=0.009) in the Neisseriales order among controls (~10%), GFD patients (~4%), and CD patients (~26%). (d) Also at family level, the Neisseriaceae family was significantly less abundant (P=0.01) in controls (~10%) and GFD patients (4%) than in CD patients (~32%). (e) At genus level, Neisseria was significantly more abundant (P=0.03) in active CD patients (26%) than in controls (10%) and GFD patients (4%). Taxa (in parentheses) refer to the phylum to which the genus belongs. The data reported are filtered by a frequency higher than 1%. Error bars indicate standard error. Asterisks refer to taxa that differed significantly among the three groups (P<0.05, analysis of variance).
Figure 2Alpha rarefaction curves and beta diversity analysis in controls, in active and in gluten-free diet (GFD) celiac disease (CD) patients. (a) Alpha rarefaction curves at normalization by depth of 792 sequences per sample (obtained with the QIIME pipeline, Supplementary Materials and Methods) showed that bacterial community richness did not differ between CD patients and controls. (b) Principal-coordinates analysis applied to the unweighted and (c) weighted UniFrac distances shows a difference between CD patients and controls. In fact, both active CD and GFD patients are distinct from controls, which moreover had a random distribution (P=0.017, R2=0.06; ADONIS and P=0.014, R2=0.10; ADONIS, respectively). Filled blue squares refer to a subgroup of control subjects affected by gastroesophageal reflux disease, chronic gastritis, or fibromatous uterus, whereas opened blue squares refer to a subgroup of controls affected by dyspepsia or irritable bowel syndrome; both these control groups are CD negative. (d) This figure shows the viability of N. flavescens species (arrows) in duodenal mucosa cultures from active CD patients (top panel), whereas the bacterium did not grow in duodenal cultures from control subjects (bottom panel).
Figure 3N. flavescens internalization in epithelial cells. N. flavescens isolated from the gut mucosa of active celiac disease (CD) patients (CD-Nf) seldom colocalized with lysosomes (LAMP-1) in CaCo-2 cells, whereas N. flavescens isolated from the oropharynx of control subjects (CTR-Nf) clearly colocalized with LAMP-1. The figure (which is representative of three independent experiments) shows the results obtained 6 h after infection of CaCo-2 cells with N. flavescens (multiplicity of infection 1:50) isolated from 2 active CD patients (CD-Nf1/Nf7) and from a control subject (CTR-Nf10). An antibody against N. flavescens was used before permeabilization followed by a secondary Cy5-conjugated antibody and, after permeabilization, with an Alexafluor-546-conjugated secondary antibody (red). We used LAMP-1 and an Alexafluor-488 (green)-conjugated secondary antibody to detect endo/lysosomes. Merge and InSet images show colocalization of the bacteria with lysosomes (white arrows). Uninfected CaCo-2 cells (NO bacteria), stained with anti N. meningitidis antibody and processed for immunofluorescence as the other samples, served as control of the procedure. Samples were analyzed by confocal microscopy with × 63 oil immersion objective. Bars = 10 μm.
Figure 4N. flavescens (Nf) isolated from celiac disease (CD) patients induce a pro-inflammatory phenotype on dendritic cells. Filtered bacterial lysates from Neisseria flavescens (Nf), isolated from 5 active celiac patients (CD-Nf1, 2, 3, 7, and 8), promoted the production of pro-inflammatory cytokines by dendritic cells (DCs). CD11c+ DCs isolated from the spleens of C57B6 mice were cultured for 48 h in the presence of retinoic acid (RA) and transforming growth factor-β (TGF-β) with filtered Nf lysates from three active CD patients (a). All three tested bacterial lysates promoted the production of interleukin (IL)-12p40 by murine DCs, whereas untreated (stars upon horizontal bars), lipopolysaccharide (LPS)-treated (stars), and LGG-treated DCs did not (b). Human monocyte-derived DCs were cultured for 48 h in the presence of RA and TGF-β with filtered Nf lysates isolated from active CD patients (c). Tumor necrosis factor-α (TNF-α) levels were higher in supernatants of human DCs treated with Nf 1, Nf 7, and Nf 8 bacterial strains isolated from small intestinal biopsies of CD patients, and in those challenged with Nf10 isolated from a pharyngeal swab of a control subject (d), than in those treated with bacterial LPS, used as a pro-inflammatory positive control (stars upon horizontal bars) and in untreated (UN) cells (P<0.0001 for each of the treatments). IL-12p40 levels were higher in supernatants of human DCs challenged with Nf1,2,3 filtered lysates than in those treated with bacterial LPS (stars) used as a pro-inflammatory positive control and in untreated (UN) cells (stars upon horizontal bars) (e). Dot plots represent values from three independent experiments. Each experiment was performed in duplicate. A two-way analysis of variance was performed to check for inter-group differences. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001.
CD-Nf challengea induces duodenal mucosa from control subjects to secrete pro-inflammatory cytokines in supernatants
| No treatment | 23.44 (9.34) | 10.10 (0.48) | 135.29 (72.08) | 38.69 (8.86) | 8.42 (5.98) | 5.17 (4.18) | 6.43 (1.22) |
| Challenge with CD- | 59.23 (2.40) | 14.83 (2.12) | 253.34 (147.57) | 50.39 (11.84) | 11.16 (7.92) | 7.12 (5.01) | 10.61 (2.15) |
| Challenge with CD- | 107.94 (2.34) | 23.24 (2.49) | 452.66 (19.74) | 106.01 (3.68) | 25.01 (3.80) | 21.06 (14.15) | 14.71 (2.43) |
| 0.249 | 0.320 | 0.353 | 0.082 | ||||
IFN-γ, interferon-γ IL-6, interleukin-6; TNF-α, tumor necrosis factor-α.
Ex- vivo mucosal explants from three control subjects were treated for 6 h with CD-Nf at a multiplicity of infection (MOI) 1:10 and 1:50, and then levels of inflammatory cytokines were measured in supernatants of those treated with respect to untreated biopsies. Differences between mean levels were tested by the Friedman test with Bonferroni correction, and the p value is reported under each column.
Boldface type indicates statistically significant differences among groups (P<0.05).